Salarius Pharmaceuticals announces the presentation of a poster related to the company’s novel molecular glue, SP-3164, at the European Hematology Association 2023 Hybrid Conference, which was held in Frankfurt, Germany and virtually June 8-11, 2023. Research presented on June 9, 2023 by Aundrietta Duncan, Ph.D., director of non-clinical development at Salarius, in a poster titled “A Novel Cereblon-Binding Molecular Glue, Sp-3164, Shows Preclinical Activity In Non-Hodgkin Lymphomas” and available here, demonstrated Potent degradation of Ikaros and Aiolos in peripheral blood mononuclear cells within 2 hours of dosing, which increased in a dose- and time-dependent manner over 24 hours. SP-3164 does not negatively impact PBMC at clinically relevant concentrations up to 96 hours post-treatment. In addition to having direct antitumor effects, SP-3164 also induces an anticancer immunomodulatory effect as demonstrated through the induction of cytokine secretion in human T cells following treatment. In addition, new quantitative proteomic data revealed that in Jeko-1 cells, SP-3164 induces twice the degradation of target proteins I/A at 1/10th the dose of lenalidomide, providing further support for the development of SP-3164 in relapsed refractory non-Hodgkin lymphoma.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SLRX:
- Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress
- Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
- Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
- Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update
- FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma
